Transcriptomics

Dataset Information

3

Identification of differentially expressed genes upon treatment with Eltrombopag in HL60 cells


ABSTRACT: Identification of differentially expressed genes upon treatment with Eltrombopag in HL60 cells. HL60 cells were untreated, or treated with 3ug/ml of Eltrombopag for 36 hrs in RPMI with 10% FBS HL60 cells were untreated, or treated with 3ug/ml of Eltrombopag for 36 hrs in RPMI with 10% FBS

ORGANISM(S): Homo sapiens  

SUBMITTER: Boris Bartholdy   Britta Will  Ulrich G Steidl  Michael Roth  Constantine S Mitsiades 

PROVIDER: E-GEOD-37580 | ArrayExpress | 2012-06-24

SECONDARY ACCESSION(S): GSE37580PRJNA161883

REPOSITORIES: GEO, ArrayExpress

altmetric image

Publications

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.

Roth Michael M   Will Britta B   Simkin Guillermo G   Narayanagari Swathi S   Barreyro Laura L   Bartholdy Boris B   Tamari Roni R   Mitsiades Constantine S CS   Verma Amit A   Steidl Ulrich U  

Blood 20120524 2


Eltrombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been approved recently for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura. Prior studies have shown that EP stimulates megakaryopoiesis in BM cells from patients with acute myeloid leukemia and myelodysplastic syndrome, and the results also suggested that it may inhibit leukemia cell growth. In the present study, we studied the effects of EP on leukemia ce  ...[more]

Similar Datasets

2019-03-29 | PXD012053 | Pride
| GSE110189 | GEO
2015-06-17 | E-GEOD-61670 | ArrayExpress
2009-11-28 | E-GEOD-15741 | ArrayExpress
2010-03-23 | E-GEOD-20540 | ArrayExpress
2011-04-19 | E-GEOD-22667 | ArrayExpress
2016-06-01 | PXD004085 | Pride
| GSE21004 | GEO
| GSE20733 | GEO
2011-04-19 | E-GEOD-22632 | ArrayExpress